Teo K W, Yuan N K, Tan W B, Parameswaran R
National University Hospital , Singapore.
Ann R Coll Surg Engl. 2017 Jul;99(6):479-484. doi: 10.1308/rcsann.2017.0072.
INTRODUCTION Many studies have addressed the accuracy of prognostic scoring systems in the treatment of differentiated thyroid cancers as a whole but few have addressed this issue in patients with follicular thyroid cancer (FTC) alone. The aim of this study was to establish the accuracy of the various scoring systems in determining the overall and disease free survival of FTC patients in Singapore. METHODS Retrospective review was undertaken of 82 patients with FTC treated at a single tertiary institution between January 2000 and December 2014. Demographic, clinical, pathological and treatment outcomes were analysed. Prognostic scoring systems evaluated for the cohort included TNM (Tumour, Nodes, Metastases), AGES (Age, Grade, Extent, Size), MACIS (Metastases, Age, Completeness of resection, Invasion, Size), AMES (Age, Metastases, Extent, Sex) and EORTC (European Organisation for Research and Treatment of Cancer). Statistical analysis was performed by plotting Kaplan-Meier survival curves and using the Cox proportional hazards model. RESULTS There were 29 male and 53 female patients with a mean age of 48 years. The mean follow-up duration was 88 months and there were 7 deaths (9%). The ten-year overall survival rate was 90%. Factors predictive of survival on univariate analysis were age, size of tumour, invasiveness, completeness of resection, metastasis, external beam radiotherapy, and risk scores using the AGES and MACIS scoring systems (p<0.05). On multivariate analysis, AGES and MACIS provided the best prognostic information. CONCLUSIONS MACIS is the best prognostic scoring system currently available for FTC and it is superior to other scoring systems in term of guiding management. The scoring systems require further development to accommodate variations in clinical practice globally and to improve the prognostic accuracy.
引言
许多研究探讨了预后评分系统在分化型甲状腺癌整体治疗中的准确性,但很少有研究单独针对滤泡状甲状腺癌(FTC)患者探讨这一问题。本研究的目的是确定各种评分系统在预测新加坡FTC患者总生存期和无病生存期方面的准确性。
方法
对2000年1月至2014年12月在一家三级医疗机构接受治疗的82例FTC患者进行回顾性研究。分析了患者的人口统计学、临床、病理和治疗结果。对该队列评估的预后评分系统包括TNM(肿瘤、淋巴结、转移)、AGES(年龄、分级、范围、大小)、MACIS(转移、年龄、切除完整性、侵犯、大小)、AMES(年龄、转移、范围、性别)和EORTC(欧洲癌症研究与治疗组织)。通过绘制Kaplan-Meier生存曲线并使用Cox比例风险模型进行统计分析。
结果
共有29例男性和53例女性患者,平均年龄48岁。平均随访时间为88个月,有7例死亡(9%)。十年总生存率为90%。单因素分析中预测生存的因素包括年龄、肿瘤大小、侵袭性、切除完整性、转移、外照射放疗以及使用AGES和MACIS评分系统的风险评分(p<0.05)。多因素分析中,AGES和MACIS提供了最佳的预后信息。
结论
MACIS是目前可用于FTC的最佳预后评分系统,在指导治疗方面优于其他评分系统。评分系统需要进一步发展,以适应全球临床实践的差异并提高预后准确性。